These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24817484)

  • 1. Experiences with the use of varenicline in daily practice in the Netherlands: a prospective, observational cohort study.
    Oosterhuis I; Härmark L; van Puijenbroek E
    Drug Saf; 2014 Jun; 37(6):449-57. PubMed ID: 24817484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand.
    Harrison-Woolrych M; Ashton J
    Drug Saf; 2011 Sep; 34(9):763-72. PubMed ID: 21830838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England.
    Buggy Y; Cornelius V; Fogg C; Kasliwal R; Layton D; Shakir SA
    Drug Saf; 2013 Jul; 36(7):521-31. PubMed ID: 23657823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study.
    Kasliwal R; Wilton LV; Shakir SA
    Drug Saf; 2009; 32(6):499-507. PubMed ID: 19459717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
    Tonstad S
    J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness.
    Purvis TL; Mambourg SE; Balvanz TM; Magallon HE; Pham RH
    Ann Pharmacother; 2009 May; 43(5):862-7. PubMed ID: 19383936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observational study of safety and efficacy of varenicline for smoking cessation among Filipino smokers.
    Park PW; Casiano EM; Escoto L; Claveria AM
    Curr Med Res Opin; 2011 Oct; 27(10):1869-75. PubMed ID: 21838412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of varenicline as an aid to smoking cessation in UK general practice - a THIN database study.
    Blak BT; Wilson K; Metcalfe M; Maguire A; Hards M
    Curr Med Res Opin; 2010 Apr; 26(4):861-70. PubMed ID: 20144137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study.
    Boudrez H; Gratziou C; Messig M; Metcalfe M
    Curr Med Res Opin; 2011 Apr; 27(4):769-75. PubMed ID: 21294601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varenicline in smoking cessation.
    Tonstad S; Rollema H
    Expert Rev Respir Med; 2010 Jun; 4(3):291-9. PubMed ID: 20524911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD; Dugan SE
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.
    Tonstad S; Davies S; Flammer M; Russ C; Hughes J
    Drug Saf; 2010 Apr; 33(4):289-301. PubMed ID: 20297861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary benefit-risk assessment of varenicline in smoking cessation.
    Cahill K; Stead L; Lancaster T
    Drug Saf; 2009; 32(2):119-35. PubMed ID: 19236119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.
    Bolliger CT; Issa JS; Posadas-Valay R; Safwat T; Abreu P; Correia EA; Park PW; Chopra P
    Clin Ther; 2011 Apr; 33(4):465-77. PubMed ID: 21635992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.
    Williams JM; Anthenelli RM; Morris CD; Treadow J; Thompson JR; Yunis C; George TP
    J Clin Psychiatry; 2012 May; 73(5):654-60. PubMed ID: 22697191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.